AdventHealth, Moffitt form collaboration

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Moffitt Cancer Center and AdventHealth are partnering to provide cancer treatment and better access to cancer prevention, education, cancer screenings and early phase clinical trials for patients in Florida.

The partnership will develop a cancer research agenda shared across both organizations, which will include expanding research activities and recruitment of innovative cancer investigators to the AdventHealth Orlando and Celebration campuses.

The two organizations plan to establish a clinical research facility and chemotherapy/immunotherapy infusion program at AdventHealth Celebration, focused on solid tumor malignancies and malignant hematology, which will allow Central Florida patients to receive critical treatments closer to home.

At AdventHealth Celebration, researchers from both organizations will conduct early phase clinical studies—the first and only phase I site in Central Florida.

This partnership extends to AdventHealth’s West Florida division as well, where a new Moffitt outpatient satellite cancer center is under construction at AdventHealth Wesley Chapel.

Table of Contents

YOU MAY BE INTERESTED IN

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login